PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28554528-10	2017	In contrast, repeated lobeline treatment significantly increased both BrdU- and BDNF-positive cells.	Lobeline	22-30	brain derived neurotrophic factor	Mus musculus	80-84	
25451721-8	2015	Lobeline (1 mg/kg) treatment prevented CUS-induced reduction in BDNF expression and cell proliferation in the hippocampus.	Lobeline	0-8	brain derived neurotrophic factor	Mus musculus	64-68	
24682499-6	2014	Furthermore, we determined the effects of repeated treatment with lobeline or a selective alpha4beta2 nAChR ligand 3-(pyridine-3-yl)-cytisine on brain-derived neurotrophic factor (BDNF) and phosphorylated cAMP-responsive element binding (p-CREB) protein expression in the hippocampus.	Lobeline	66-74	brain derived neurotrophic factor	Mus musculus	145-178	
24682499-10	2014	Further, repeated treatment with lobeline or 3-(pyridine-3-yl)-cytisine decreased immobility time in the FST and reduced withdrawal-induced increased BDNF and p-CREB expression in the hippocampus.	Lobeline	33-41	brain derived neurotrophic factor	Mus musculus	150-154	
24682499-11	2014	CONCLUSIONS: Taken together, our results indicate that lobeline attenuated nicotine withdrawal-induced depression-like behavior likely by targeting brain nAChRs, noradrenergic neurotransmission, and/or hippocampal BDNF.	Lobeline	55-63	brain derived neurotrophic factor	Mus musculus	214-218